Related Experiment Video
Updated: Aug 24, 2026
Myocardial Infarction by Percutaneous Embolization Coil Deployment in a Swine Model
Published on: November 4, 2021
Angiographic demonstration of coronary dethrombosis with eptifibatide
Alessandro Colombo1, Francesco Lavarra, Paolo Danna
1Cardiology Department, Luigi Sacco Hospital, Milan, Italy. emodinamica@hsacco.it
Insights
In acute coronary syndromes, antithrombotic therapy is crucial. This report details two cases showing the effectiveness of GP IIb/IIIa inhibitors like eptifibatide, with or without alteplase, in treating coronary thrombosis.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Acute coronary syndromes often involve thrombosis.
- Percutaneous coronary intervention (balloon and stents) is a common treatment.
- Antithrombotic therapy plays a vital role in managing these conditions.
Observation:
- Two clinical cases of coronary thrombosis were analyzed.
- Angiographic visualization was used to assess treatment effects.
- The impact of GP IIb/IIIa inhibitor eptifibatide was observed.
Findings:
- Eptifibatide, alone or with alteplase, demonstrated efficacy in treating coronary thrombosis.
- Angiographic findings confirmed the therapeutic effect of the antithrombotic agents.
- The study showcases the benefits of combining pharmacotherapy with interventions.
Implications:
- Vigorous antithrombotic treatment should be considered in ACS management.
- GP IIb/IIIa inhibitors offer a valuable therapeutic option for coronary thrombosis.
- These findings support the integrated approach to treating complex coronary artery disease.
Abstract:
When dealing with acute coronary syndromes, the interventionists often go straight to balloon and stents, because they work quick and well in the majority of cases. However, it is not to forget that vigorous antithrombotic treatment is frequently highly beneficial in these settings. We report here on two clinical cases of coronary thrombosis in which we could appreciate on the angiograms the effect of GP IIb/IIIa inhibitor eptifibatide alone or in conjunction with alteplase.
